Genetic alterations in JmjCs, including KDM2A, KDM2B, KDM4A, KDM4B, KDM42C and KDM5B, have all been linked to cancer progression and these enzymes have been suggested as chemotherapeutic targets [64–73]. This evidence concerns the gene KDM2B and cancer.